Crowdfunding Opportunity to co-invest in Era7 Bioinformatics with a Venture Capital specialized in Life Sciences
Era7 Bioinformatics announces today the opportunity of crowdfunding co-investment with a Venture Capital in a 600000 Euros (around $660000) investment round. A Spanish Venture Capital specialized in Life Sciences takes part in this round and the rest is offered to private investors through the equity crowdfunding platform for biotech projects Capital Cell:
“With this mixed approach we get the best of both worlds, Venture Capital and private investors using crowdfunding. Venture Capital contributes experience and knowledge in the sector in addition to funding, and the crowdfunding opens the possibility to invest to small private investors, democratizing the investment in fast growing biotech start-ups. And with this combination the private investors have double guarantee since our company has been analyzed and validated by a specialized Venture Capital and by the Capital Cell team” Declared Dr. Eduardo Pareja, Era7 Bioinformatics’ CEO.
The genomics revolution has changed Biology and Medicine. Genomics generates continuously massive data that it is needed to analyze using bioinformatics methods to translate it in comprehensible and ready to interpretation data useful for researchers and clinicians. It has provoked a problem of handling and analysis of BIG DATA in Genomics.
Bacteria are all over the world: in the air, in the soil, in the plants, in all living organisms and are crucial in Medicine, Human health, Agriculture, Agrifood industry, Alternative energies or Environmental sciences.
Just now we are assisting to a new revolution of the genomics: the Microbiome revolution. The Microbiome is the set of bacteria that live in an organism, in an environmental niche (a lake, a beach, a crop) or in a place (your home, a hospital, your mobile phone). To know the Microbiome is very important for health, on one hand for fighting against pathogen bacteria and, on the other hand, to promote the beneficial bacteria that maintain a healthy balance in our tissues.
The Business Plan to be funded includes mainly a business development effort in United States, where Era7 Bioinformatics has already a subsidiary company, and an optimization of the integration and automation of the Era7 Bioinformatics tools for Microbiome analysis and Bacterial genomics and metagenomics. All of them to support the expected sales increment.
“There are many reasons to invest in our company but I would mention one: we have an already proven business model and we are already present in the USA market with a high level of acceptation. Now, it’s a matter of scaling and this expansion plan is going to allow us to develop the needed actions to be successful” Added Dr. Eduardo Pareja.
About Era7 Bioinformatics
Era7 Bioinformatics (www.era7bioinformatics.com) is a leading Bioinformatics company focused on Microbiome, Antibiotics Resistance and Bacterial Genomics that analyzes data from Next Generation Sequencing (NGS) technologies. Era7 is based in USA, in Cambridge MA, and in Spain, in Granada and Madrid. The Era7´s business model is based on a strong Research activity on Bacterial Genomics and metagenomics and on its expertise in Big Data analysis and Cloud Computing following an Open Source philosophy for its software developments.